KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on  consolidating medical clinics and becoming a North American leader in mental health treatments.  It is working to provide the critical infrastructure needed to develop and deliver breakthrough  mental health treatments. Currently, Ketamine One has a network of 16 clinics across North  America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is  the Company’s wholly-owned contract research division, which places it at the forefront of  premium clinical research based on the subsidiary’s 24-year history and extensive experience in  pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective  enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible  mental health therapy.